All News
Filter News
Found 605 articles
-
Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance
4/14/2022
Alzheon, Inc. announced the appointments of Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance.
-
Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio
4/14/2022
Alzheon, Inc. announced that it has completed an oversubscribed $50 million Series D round from private and institutional investors.
-
Neurodegenerative Disorders Drug Therapy Biomarkers Insight 2028
4/8/2022
Global Alzheimer's Disease Drug Biomarkers Insight 2028 Report Highlights.
-
Shares of Biogen are falling in post-market trading after the U.S. government officially announced it will limit coverage of the company’s controversial Alzheimer’s drug Aduhelm to patients in clinical trials.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Biogen will await word after submitting the final study protocol for its confirmatory Phase IV ENVISION trial of Aduhelm to the U.S. Food and Drug Administration (FDA).
-
A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.
-
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
3/30/2022
Biogen Inc. (Nasdaq: BIIB) has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration (FDA) for review and approval.
-
Lately, there has been heightened attention to briefing documents in the CNS space, a notoriously tricky area to get drugs approved, which can affect company stock prices.
-
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will face its first big test since Aduhelm as it weighs the merits of Amylyx's AMX0035 for ALS on Wednesday, March 30.
-
Biomarkers for Alzheimer's Disease
3/23/2022
Global Alzheimer's Disease Biomarkers & Clinical Trials Insight 2028 Report Highlights.
-
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Latest Findings On Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship To Clinical Outcomes And Dosing Regimens - Presented At AD/PD™ 2022 Annual Meeting
3/21/2022
Eisai Co., Ltd. and Biogen Inc. announced that the latest findings on lecanemab, an investigational anti-amyloid-beta protofibril antibody being developed for the treatment of early Alzheimer's disease, were presented at the Aβ Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases March 15-20 in Barcelona, Spain and virtually.
-
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
-
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
3/16/2022
Biogen announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM.
-
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
3/16/2022
Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease.
-
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
-
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
3/14/2022
Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM® (aducanumab-avwa).
-
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
3/11/2022
Biogen Inc. announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® injection 100 mg/mL for intravenous use, at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases, taking place March 15-20 in Barcelona, Spain and virtually.